Adrenomedullary catecholamine, pressor and chronotropic responses to human coagulation β-FXIIa mediated by endogenous kinins

Journal of Hypertension

Volumn 26, Issue 1, 2008, Pages 61-69

  Amfilochiadis, Akis A ^b   Backx, Peter H ^a,b,c   Floras, John S ^a,b,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b HEART AND STROKE FOUNDATION OF CANADA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Blood coagulation; Blood pressure; Bradykinin; Catecholamines; Hypertension; Kininogen

Indexed keywords

ADRENALIN; BRADYKININ; CATECHOLAMINE; KALLIKREIN; KININ; KININOGEN; NORADRENALIN; PROTHROMBIN A;

ADRENAL MEDULLA; ADRENALECTOMY; ADRENALIN BLOOD LEVEL; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BIOASSAY; BLOOD CLOTTING; BOLUS INJECTION; BROWN NORWAY RAT; CATECHOLAMINE RELEASE; CHRONOTROPISM; CONTROLLED STUDY; HEART RATE; HEMODYNAMICS; HYPERTENSION; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; RAT; REFLEX; SYSTOLIC BLOOD PRESSURE;

EID: 37349129637     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282f190cf     Document Type: Article

References (58)

1. Revak SD, Cochrane CG, Bouma BN, Griffin JH. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med 1978; 147:719-729.
2. Mahdi F, Madar ZS, Figueroa CD, Schmaier AH. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002; 99:3585-3596.
3. Shan J, Baguinon M, Zheng L, Krishnamoorthi R. Expression, refolding, and activation of the catalytic domain of human blood coagulation factor XII. Protein Expr Purif 2003; 27:143-149.
4. Citarella F, Ravon DM, Pascucci B, Felici A, Fantoni A, Hack CE. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur J Biochem 1996; 238:240-249.
5. Shariat-Madar Z, Mahdi F, Schmaier AH. Assembly and activation of the plasma kallikrein/kinin system: a new interpretation. Int Immunopharmacol 2002; 2:1841-1849.
6. Dunn JT, Silverberg M, Kaplan AP. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem 1982; 257:1779-1784.
7. Waeber G, Schapira M, Waeber B, Aubert JF, Nussberger J, Brunner HR. Hypotensive effect of the active fragment derived from factor XII is mediated by an activation of the plasma kallikrein-kinin system. Circ Shock 1988; 26:375-382.
8. Schmaier AH. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J Clin Invest 2002; 109:1007-1009.
9. Papageorgiou PC, Pourdjabbar A, Amfilochiadis AA, Diamandis EP, Boomsma F, Osmond DH. Are cardiovascular and sympathoadrenal effects of human 'new pressor protein' preparations attributable to human coagulation beta-FXIIa? Am J Physiol Heart Circ Physiol 2004; 286:H837-H846.
10. Amfilochiadis AA, Papageorgiou PC, Kogan N, Boomsma F, Osmond DH. Role of bradykinin B2-receptor in the sympathoadrenal effects of 'new pressor protein' related to human blood coagulation factor XII fragment. J Hypertens 2004; 22:1173-1181.
11. Gavras I, Gavras H. Hypertension, vasoactive peptides and coagulation factors. J Hypertens 2004; 22:1091-1092.
12. Osmond DH, Mavrogiannis L, Cotter BR. Potent 'new pressor protein' related to coagulation factor XII is potentiated by inhibition of angiotensin converting enzyme. J Hypertens 1998; 16:311-320.
13. Dendorfer A, Hauser W, Falias D, Dominiak P. Bradykinin increases catecholamine release via B2 receptors. Pflugers Arch 1996; 432:R99-R106.
14. Houchi H, Azuma M, Yoshizumi M, Tamaki T, Minakuchi K. Possible role of bradykinin on stimulus-secretion coupling in adrenal chromaffin cells. J Med Invest 1999; 46:1-9.
15. Case DB, Wallace JM, Keim HJ, Weber MA, Drayer JI, White RP, et al. Estimating renin participation in hypertension: superiority of convering enzyme inhibitor over saralasin. Am J Med 1976; 61:790-796.
16. Man in't Veld AJ, Wenting GJ, Schalekamp MA. Does captopril lower blood pressure in anephric patients? BMJ 1979; 2:1110.
17. Leslie BR, Case DB, Sullivan JF, Vaughan ED. Absence of blood-pressure lowering effect of captopril in anephric patients. BMJ 1980; 280:1067-1068.
18. Wenting GJ, Blankestijn PJ, Poldermans D, van Geelen J, Derkx FH, Man in't Veld AJ, Schalekamp MA. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotension converting enzyme is important. Am J Cardiol 1987; 59:92D-97D.
19. Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353:2008-2013.
20. Rhaleb NE, Yang XP, Nanba M, Shesely EG, Carretero OA. Effect of chronic blockade of the kallikrein-kinin system on the development of hypertension in rats. Hypertension 2001; 37:121-128.
21. Hayashi I, Hoshiko S, Makabe O, Oh-ishi S. A point mutation of alanine 163 to threonine is responsible for the defective secretion of high molecular weight kininogen by the liver of Brown Norway Katholiek rats. J Biol Chem 1993; 268:17219-17224.
22. Yang X-P, Liu Y-H, Scicli GM, Webb CR, Carrotero OA. Role of kinins in the cardioprotective effects of preconditioning. Study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 1997; 30:735-740.
23. Liu Y-H, Yang X-P, Mehta D, Bulagannawar M, Scicli GM, Carrotero OA. Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats. Am J Physiol Heart Circ Physiol 2000; 278:H507-H514.
24. Yamaguchi I, Kopin IJ. Plasma catecholamine and blood pressure responses to sympathetic stimulation in pithed rats. Am J Physiol 1979; 237:H305-H310.
25. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44:1-80.
26. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci 1994; 87:567-574.
27. Mavrogiannis L, Trambakoulos DM, Boomsma F, Osmond DH. The sympathoadrenal system mediates the blood pressure and cardiac effects of human coagulation factor XII-related 'new pressor protein'. Can J Cardiol 2002; 18:1077-1086.
28. Blais C Jr, Marceau F, Rouleau JL, Adam A. The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. Peptides 2000; 21:1903-1940.
29. Uchida Y, Katori M. Differential assay method for high molecular weight and low molecular weight kininogens. Thromb Res 1979; 15:127-134.
30. Wakade AR. Multiple transmitter control of catecholamine secretion in rat adrenal medulla. Adv Pharmacol 1998; 42:595-598.
31. Saito H, Hamilton SM, Tavill AS, Goodnough LT, Louis L, Angell A. Synthesis and release of Hageman factor (factor XII) by the isolated perfused rat liver. J Clin Invest 1983; 72:948-954.
32. Saito H, Ratnoff OD. Comparative studies of Hageman factor (factor XII) in mammalian plasmas by immunological techniques. Proc Soc Exp Biol Med 1979; 161:412-416.
33. Yang EK, Lee WJ, Park YY, Ahn DK, Park JS, Kim HJ. Effects of chronic central administration of losartan on the cardiovascular and hormonal responses to hemorrhage in conscious rats. Regul Pept 1996; 67:107-113.
34. Scheurink AJ, Steffens AB, Bouritius H, Dreteler GH, Bruntink R, Remie R, Zaagsma J. Adrenal and sympathetic catecholamines in exercising rats. Am J Physiol 1989; 256:R155-R160.
35. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006; 95:1003-1010.
36. Printz MP, Rasmussen K. Modulation of adrenal chromaffin cell intracellular calcium by angiotensin, bradykinin and endothelin. Endocrinol Exp 1990; 24:55-61.
37. O'Sullivan AJ, Burgoyne RD. A comparison of bradykinin, angiotensin II and muscarinic stimulation of cultured bovine adrenal chromaffin cells. Biosci Rep 1989; 9:243-252.
38. Bouallegue A, Yamaguchi N. Nitric oxide inhibits the bradykinin B2 receptor-mediated adrenomedullary catecholamine release but has no effect on adrenal blood flow responses in vivo. J Pharmacol Sci 2005; 98:151-160.
39. von Kanel R, Dimsdale JE. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. Eur J Haematol 2000; 65:357-369.
40. Emanueli C, Maestri R, Corradi D, Marchione R, Minasi A, Tozzi MG, et al. Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation 1999; 100:2359-2365.
41. Meneton P, Bloch-Faure M, Hagege AA, Ruetten H, Huang W, Bergaya S, et al. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci U S A 2001; 98:2634-2639.
42. Oh-ishi S, Hayashi I, Hosiko S, Makabe O. Molecular mechanism of kininogen deficiency in Brown Norway Katholiek rats. Braz J Med Biol Res 1994; 27:1803-1815.
43. Yayama K, Kunimatsu N, Teranishi Y, Takano M, Okamoto H. Tissue kallikrein is synthesized and secreted by human vascular endothelial cells. Biochim Biophys Acta 2003; 1593:231-238.
44. Yayama K, Nagaoka M, Takano M, Okamoto H. Expression of kininogen, kallikrein and kinin receptor genes by rat cardiomyocytes. Biochim Biophys Acta 2000; 1495:69-77.
45. Tsuchida S, Miyazaki Y, Matsusaka T, Hunley TE, Inagami T, Fogo A, Ichikawa I. Potent antihypertrophic effect of the bradykinin B2 receptor system on the renal vasculature. Kidney Int 1999; 56:509-516.
46. Hermann A, Arnhold M, Kresse H, Neth P, Fink E. Expression of components of the kallikrein-kinin system in human cell lines. Immunopharmacology 1999; 45:135-139.
47. Mimura T, Hayashi I, Hoshino T, Oh-ishi S. Demonstration of high-molecular-weight kininogen in kininogen-deficient rat kidneys. J Biochem (Tokyo) 1994; 116:59-63.
48. Dabisch PA, Kerut EK, Liles JT, Wien G, Smith M, Patterson M, et al. Responses to bradykinin are mediated by NO-independent mechanisms in the rat hindlimb vascular bed. Pharmacol Res 2004; 50:575-584.
49. Papageorgiou PC, Simos D, Boomsma F, Rojkjaer R, Osmond DH. ACE-regulated, noncholinergic sympathoadrenal catecholamine release mediates the cardiovascular actions of human NPP related to coagulation β-FXIIa. Can J Cardiol 2007; In press.
50. Girolami A, Morello M, Girolami B, Lombardi AM, Bertolo C. Myocardial infarction and arterial thrombosis in severe (homozygous) FXII deficiency: no apparent causative relation. Clin Appl Thromb Hemost 2005; 11:49-53.
51. Pauer HU, Renne T, Hemmerlein B, Legler T, Fritzlar S, Adham I, et al. Targeted deletion of murine coagulation factor XII gene - a model for contact phase activation in vivo. Thromb Haemost 2004; 92:503-508.
52. Alving BM, Hojima Y, Pisano JJ, Mason BL, Buckingham RE, Mozen MM, Finlayson JS. Hypotension associated with prekallikrein activator (Hageman-Factor Fragments) in plasma protein fraction. N Engl J Med 1978; 299:66-70.
53. Taucher M, Grassler J, Kuhne H, Scheuch DW. Effect of kallikrein-kinin system activation by factor XII f pretreatment on experimental hemorrhagic shock. Z Med Lab Diagn 1990; 31:13-17.
54. Grundt H, Nilsen DW, Hetland O, Valente E, Fagertun HE. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 2004; 147:260-266.
55. Schaefer RM, Schaefer L, Horl WH. Anaphylactoid reactions during hemodialysis. Clin Nephrol 1994; 42 (Suppl 1):S44-S47.
56. Kohler HP, Carter AM, Stickland MH, Grant PJ. Levels of activated FXII in survivors of myocardial infarction - association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 1998; 79:14-18.
57. Colhoun HM, Zito F, Norman Chan N, Rubens MB, Fuller JH, Humphries SE. Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis 2002; 163:363-369.
58. Altieri P, Devoto E, Spallarossa P, Rossettin P, Garibaldi S, Bertero G, et al. Acute coronary syndromes do not promote prolonged in vivo FXII-dependent prothrombotic activity. Thromb Res 2005; 115:650-672.